CN114569547A - 布林西多福韦的制剂 - Google Patents

布林西多福韦的制剂 Download PDF

Info

Publication number
CN114569547A
CN114569547A CN202210134248.1A CN202210134248A CN114569547A CN 114569547 A CN114569547 A CN 114569547A CN 202210134248 A CN202210134248 A CN 202210134248A CN 114569547 A CN114569547 A CN 114569547A
Authority
CN
China
Prior art keywords
concentration
brindofovir
solution
brincidofovir
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210134248.1A
Other languages
English (en)
Chinese (zh)
Inventor
穆罕默德·安娜若·卡比尔
奥丁·约翰·纳德尔
厄玛·玛丽莎·格罗西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emergency Biological Defense Action Lansing LLC
Original Assignee
Chimerix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chimerix Inc filed Critical Chimerix Inc
Publication of CN114569547A publication Critical patent/CN114569547A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202210134248.1A 2016-06-28 2017-06-28 布林西多福韦的制剂 Pending CN114569547A (zh)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201662355844P 2016-06-28 2016-06-28
US62/355,844 2016-06-28
US201662394665P 2016-09-14 2016-09-14
US62/394,665 2016-09-14
US201762446213P 2017-01-13 2017-01-13
US62/446,213 2017-01-13
US201762465053P 2017-02-28 2017-02-28
US62/465,053 2017-02-28
US201762507397P 2017-05-17 2017-05-17
US62/507,397 2017-05-17
US201762512825P 2017-05-31 2017-05-31
US62/512,825 2017-05-31
PCT/US2017/039804 WO2018005676A1 (en) 2016-06-28 2017-06-28 Formulations of brincidofovir
CN201780040478.9A CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780040478.9A Division CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Publications (1)

Publication Number Publication Date
CN114569547A true CN114569547A (zh) 2022-06-03

Family

ID=59313330

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202210134248.1A Pending CN114569547A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN201780040478.9A Pending CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202410393564.XA Pending CN118416082A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202411127002.7A Pending CN119139329A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201780040478.9A Pending CN109475497A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202410393564.XA Pending CN118416082A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂
CN202411127002.7A Pending CN119139329A (zh) 2016-06-28 2017-06-28 布林西多福韦的制剂

Country Status (11)

Country Link
US (3) US20170368082A1 (https=)
EP (2) EP4295853A3 (https=)
JP (3) JP6878473B2 (https=)
CN (4) CN114569547A (https=)
AU (2) AU2017290703B2 (https=)
DK (1) DK3474822T3 (https=)
ES (1) ES3037596T3 (https=)
FI (1) FI3474822T3 (https=)
PL (1) PL3474822T3 (https=)
PT (1) PT3474822T (https=)
WO (1) WO2018005676A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8962829B1 (en) 2013-11-15 2015-02-24 Chimerix, Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
AU2017290703B2 (en) * 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN114073772A (zh) * 2020-08-18 2022-02-22 上海市公共卫生临床中心 铁螯合剂在制备用于治疗或预防多瘤病毒感染的药物中的用途
CN114558022B (zh) * 2022-02-16 2023-11-17 华中农业大学 布林西多福韦在制备抗伪狂犬病毒药物中的应用
CN114732821A (zh) * 2022-04-24 2022-07-12 华中农业大学 西多福韦的前药在制备防治非洲猪瘟药物中的应用
JP7417339B1 (ja) * 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療
AU2024353056A1 (en) * 2023-09-29 2026-04-23 Symbio Pharmaceuticals Limited Brincidofovir for treatment of multiple sclerosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2747954C (en) 1999-12-03 2014-02-25 The Regents Of The University Of California Phosphonate compounds
JP4136340B2 (ja) * 2000-08-18 2008-08-20 武田薬品工業株式会社 注射剤
US8642577B2 (en) 2005-04-08 2014-02-04 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
EP2842559A3 (en) 2005-04-08 2015-03-18 Chimerix, Inc. Compounds, compositions and methods for the treatment of viral infections and other medical disorders
AU2008246195B2 (en) * 2007-04-27 2014-06-05 Emergent Biodefence Operations Lansing Llc Methods of Reducing Nephrotoxicity in Subjects Administered with Nucleoside Phosphonates
JP2011116658A (ja) 2008-03-13 2011-06-16 Chemo-Sero-Therapeutic Research Inst 豚萎縮性鼻炎用薬剤の製造方法
WO2011011519A1 (en) 2009-07-21 2011-01-27 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
CA2770282A1 (en) 2009-08-03 2011-02-10 Chimerix, Inc. Composition and methods of treating viral infections and viral induced tumors
CA2779473C (en) 2009-10-30 2016-08-16 Chimerix, Inc. Methods of treating viral associated diseases
WO2011066684A1 (zh) * 2009-12-03 2011-06-09 江苏恒瑞医药股份有限公司 伊立替康或盐酸伊立替康脂质体及其制备方法
US20110263536A1 (en) 2010-04-22 2011-10-27 Chimerix, Inc. Methods of Treating Orthopox Virus Infections and Associated Diseases
WO2012031045A2 (en) 2010-08-31 2012-03-08 Chimerix, Inc. Phosphonate ester derivatives and methods of synthesis thereof
WO2013163509A1 (en) 2012-04-27 2013-10-31 Chimerix, Inc. A method of mitigating virus associated end-organ damage
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
US8962829B1 (en) * 2013-11-15 2015-02-24 Chimerix, Inc. Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof
AU2017290703B2 (en) * 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANKIT BAHETI: "Excipients used in lyophilization of small molecules", 《J. EXCIPIENTS AND FOOD CHEM》 *
PHILADELPHIA COLLEGE OF PHARMAC AND SCIENCE,: "《Remington:The science and Practice of Pharmacy,21st Edition》", 31 December 2006 *

Also Published As

Publication number Publication date
JP7407984B2 (ja) 2024-01-04
AU2017290703A1 (en) 2018-12-13
ES3037596T3 (en) 2025-10-03
EP3474822B1 (en) 2025-07-09
US12485131B2 (en) 2025-12-02
CN118416082A (zh) 2024-08-02
JP2019519570A (ja) 2019-07-11
EP4295853A2 (en) 2023-12-27
EP4295853A3 (en) 2024-03-06
AU2017290703B2 (en) 2023-03-30
AU2023204117B2 (en) 2025-03-20
JP2021143178A (ja) 2021-09-24
CN109475497A (zh) 2019-03-15
US20230210873A1 (en) 2023-07-06
CA3024886A1 (en) 2018-01-04
JP6878473B2 (ja) 2021-05-26
FI3474822T3 (fi) 2025-08-15
EP3474822A1 (en) 2019-05-01
JP2023033538A (ja) 2023-03-10
PT3474822T (pt) 2025-08-21
US20170368082A1 (en) 2017-12-28
US20200138835A1 (en) 2020-05-07
PL3474822T3 (pl) 2025-11-03
WO2018005676A1 (en) 2018-01-04
AU2023204117A1 (en) 2023-07-13
JP7221485B2 (ja) 2023-02-14
CN119139329A (zh) 2024-12-17
DK3474822T3 (da) 2025-08-18

Similar Documents

Publication Publication Date Title
JP7221485B2 (ja) ブリンシドフォビルの製剤
JP6797876B2 (ja) 治療薬のｃｎｓ送達
EP3505154B1 (en) Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
TR201810815T4 (tr) Tnf-alfa antikorlarının farmasötik formülasyonları.
US10117830B2 (en) Stable parenteral DNJ compositions
EP4142770B1 (en) Semaglutide for the treatment of non-alcoholic steatohepatitis
EP4461364A2 (en) Laquinimod formulation for ocular use
WO2004096261A1 (es) Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
Su et al. Evaluation of the efficacy, toxicity and safety of vinorelbine incorporated in a lipid emulsion
HK40115807A (zh) 布林西多福韦的制剂
HK40075964A (en) Formulations of brincidofovir
HK40120600A (zh) 布林西多福韦的制剂
EP3746047B1 (en) Injectable composition
HK40105712A (en) Formulations of brincidofovir
CA3024886C (en) Formulations of brincidofovir
HK40005624B (en) Formulations of brincidofovir
HK40005624A (en) Formulations of brincidofovir
EP3846777A1 (en) Medroxyprogesterone acetate injectable compositions and methods of use
JP2007506683A (ja) ヒト成長ホルモン剤およびその調整方法と使用方法
Azri‐Meehan et al. Repeated‐Dose Toxicity Studies in Nonclinical Drug Development
KR20150030761A (ko) 화합물 1-(6-｛[6-(4-플루오로페닐)[1,2,4]트리아졸로[4,3-b]피리다진-3-일]술파닐｝-1,3-벤조티아졸-2-일)-3-(2-모르폴린-4-일에틸)우레아를 포함하는 항종양 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40075964

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240104

Address after: Delaware, USA

Applicant after: Emergency Biological Defense Action Lansing LLC

Address before: North Carolina, USA

Applicant before: CHIMERIX, Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220603